2023 Annual Report

The peak professional body for infectious diseases and clinical microbiology in Australasia.

ASID AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES

Explore More
⟶

Our Annual Report

We are the peak professional body for infectious diseases and microbiology in Australasia and a key stakeholder for government departments, medical colleges and other societies, including international organisations. Our members include Infectious Diseases Physicians, Clinical Microbiologists, Scientists, Infection Control Practitioners, Public Health Physicians, Sexual Health Physicians, Veterinarians and others eminent in the field of infectious diseases.

ASID aims to:

- Advance postgraduate education in infectious diseases in Australasia and internationally;
- Promote research in all aspects of infectious diseases; and
- Advocate for sound and evidence-based public health policy in matters related to infectious diseases.

This Annual Report provides a summary of our activities and performance for the financial year ended 31 December 2023.







Table of Contents

President's Report

In 2023 we not only delivered a fantastic ASM in Adelaide, but many other events and webinars. I'd like to thank the many members who have taken their time to help organise and run INTREPID, SIG meetings including the popular ANZPID journal club, the ICHSIG-TID Symposium, the Mycology Masterclass and more.

One of the best moments of the year was seeing the iconic Adelaide Oval scoreboard lit up with Monica Slavin's name as she was awarded Life Membership.

After the COVID pandemic, I'm sure you'll agree it was a relief to see each other again at our first fully face-to-face ASM. The organising committee threw out the rule book to deliver a different style meeting with great presentations alongside interesting SIG excursions and a Gala Ball. It was moments like these that made many of us recognise how much we missed connecting in person.

It was a year of change with the launching of the new ASID public website and members only section; and it's great to see members now using Circle. Members also launched a new ASID research exchange on Circle.

Our Advocacy and Policy Committee were kept busy ensuring ASID has a say in important issues such as The Voice, workforce, climate change, antimicrobial resistance, and Indigenous health, among others. We released several Advocacy statements and many members contributed to Work in Focus blogs showcasing the important work they do.

President's Report

Congratulations to all 2023 ASID Award recipients. It was a stellar line up of talent!

You can read more about the 2023 events, SIGs, advocacy, and award recipients further on in this report.

We held regular Board Meetings throughout 2023. I am thankful to work with such a talented and capable group of office bearers. In April we announced that Prof Rhonda Stuart, Prof David Paterson, A/Prof Julia Clark (Honorary Secretary) and Prof Allen Cheng (Past President) had completed their terms of office. Following a vote by members in March 2023, Prof Paterson was renominated and we welcomed three new Board Members - Dr Caitlin Keighley, Dr Rekha Pai Mangalore, and Professor Ben Marais. Professor Joseph Doyle was announced as ASID's new President-Elect. In July 2023 Dr Nigel Raymond, a long time NZ member, joined the Board as the NZ representative.

I'd like to thank the ASID Board and Council for their unwavering support. The ASID Secretariat has gone through a period of change and I'd like to thank them for their hard work behind the scenes to ensure everything runs smoothly.

Professor Katie Flanagan FRACP

ASID President

Our Board and Council

The Board of Directors, chaired by the President, has overall responsibility for the Society. The ASID Board features some of Australia's most distinguished experts in infectious diseases.

President
Professor Katie Flanagan
FRACP

President-Elect
Professor Joseph Doyle
FRACP FAFPHM

Honorary Treasurer
Professor Chris Blyth

Honorary Secretary
Professor David Paterson

Associate Professor Caitlin Keighley
FRCPA FRACP

Dr Rekha Pai Mangalore
FRACP

Professor Ben Marais
FRACP

Dr Nigel Raymond
FRACP

The ASID Council (comprised of the SIG Chairs and representatives from other affiliated medical societies) provide strategic input to the Board.

Dr Michelle Balm (NZ representative)
Dr Danielle Fitzpatrick (Advanced Trainee representative)
Dr Brendan McMullan (ANZPID Chair)
Dr Celia Cooper, FRACP (ANZMIG Co Chair)
Dr Karina Kennedy, FRACP (ANZMIG Co Chair)
Dr Andie Lee FRACP FRCPA (HICSIG Chair)
Prof Monica Slavin (ICHSIG Chair)
Prof Fiona Russell (VACSIG Chair)
Dr Sushena Krishnaswamy (VH2SIG Chair)
Dr Kathryn Wilks (ZOOSIG Co-Chair)
Dr KatrinaBosward (ZOOSIG Co-Chair)
Prof Steven Tong, FRACP (Clinical Research Network Chair)
Dr Indy Sandaradura FRACP FRCPA (RCPA representative)
A/Prof Paul Griffin, FRACP (JSAC Chair)
A/Prof Louise Cooley (ASA President)
Dr Beatrice Sim (Recent Fellow)

Special Interest Groups

ASID ANZPID THE AUSTRALIAN AND NEW ZEALAND PAEDIATRIC INFECTIOUS DISEASES GROUP

Chair: Dr Brendan McMullan
Deputy Chair: Dr Anita Campbell
Members: Dr Archana Koirala, Dr Nan Vasilunas, Dr Rachel Webb
Trainee Committee Member: Michelle Mahoney
ASID Clinical Research Network Committee Member: Dr Ameneh Khatami
The World Society for Pediatric Infectious Diseases (WSPID) member: Dr Phoebe Williams, Dr Linny Phuong.

ASID ANZMIG THE AUSTRALIAN AND NEW ZEALAND MYCOSES INTEREST GROUP

Co-Chairs: Dr Celia Cooper and Dr Caitlin Keighley
Immediate past Co-Chair: Assoc Prof Karina Kennedy
Secretary: Dr Sarah Kidd
Scientific Chair: Dr Lucy Crawford
Working Group Chairs: Prof Monica Slavin and Assoc Prof Sharon Chen
Trainee Representative: Dr Max Kernich
Clinical Lead: Dr Abby Douglas
Laboratory Lead: Dr Catriona Halliday

ASID CRN CLINICAL RESEARCH NETWORK

Chair: Prof Jason Trubiano
Members: Prof Steven Tong, Prof Asha Bowen, Dr Ameneh Khatami, Prof Joe Doyle, Dr J Hanson, Dr S Morpeth, Dr J Lau, Assoc Prof Gail Matthews.
Co-opted SIG Members: Prof Orla Morrissey (ANZMIG), Dr Ameneh Khatami (ANZPID), Dr Sophie Wen (VACSIG), Dr Jason Kwong (HICSIG), Assoc Prof Ben Teh (ICHSIG), Dr Sushena Krishnaswamy (VH2SIG), Dr Kathryn Wilks (ZOOSIG)

ASID HICSIG THE HEALTHCARE INFECTION CONTROL SPECIAL INTEREST GROUP

Chair: Dr Andie Lee
Immediate Previous Chair: Dr Andrew Stewardson
Members: A/Prof Caroline Marshall, Dr Rebecca McCann, Assoc Prof Deb Friedman, Dr Trish Ferguson, Assoc Prof Paul Griffin, Dr Jason Kwong, Dr Kate McCarthy, Dr Sally Roberts

Special Interest Groups

ASID ICHSIG THE IMMUNOCOMPROMISED HOST SPECIAL INTEREST GROUP

Chair: Prof Monica Slavin
Deputy Chair: Assoc Prof Ben Teh
Members: Assoc Prof Julia Clark, Dr Adam Stewart, Dr Matt Roberts, Dr Peter Boan, Assoc Prof Louise Cooley, Dr Tina Marinelli

ASID VACSIG VACCINATION SPECIAL INTEREST GROUP

Committee Chair: Prof Fiona Russell *(pictured below)*
Deputy Chair: Dr Archana Koirala
Members: Prof Katie Flanagan, Prof Michelle Giles, Prof Nigel Crawford, Dr Emma Best, Dr Sophie Wen, Assoc Prof Ben Teh, Prof Margie Danchin, Prof Peter McIntyre
Trainee Rep: Dr Phillipa Edmiston

ASID VH²SIG VIRAL HEPATITIS AND HIV SPECIAL INTEREST GROUP

Chair: Dr Sushena Krishnaswamy
Deputy Chair: Dr Emma Paige
Members: Prof Jane Davies, Prof Jenny Hoy, Prof Gail Matthews, Dr Katerina Lagios, Dr Ali Trad, Dr Sami Stewart, Dr Adam Bartlett, Dr David Griffin
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) Representative: Phoebe Schroder
Trainee Representative: Dr Naomi Whyler

ASID ZOOSIG THE ZOONOSES SPECIAL INTEREST GROUP

Co-Chairs: Dr Kathryn Wilks and Assoc Prof Katrina Bosward
Members: Prof Bart Currie, Dr Jane Dyer, Assoc Prof Thomas Gottlieb, Assoc Prof Jane Heller, Dr Richard Malik, Dr Stephen Muhi, Dr Jenny Robson, Dr Harsha Sheorey
NZ Representative: Dr Tim Blackmore
Trainee members: Dr Caitlyn Sun, Dr Andrew Nguyen



Committees

ASID ADVOCACY AND POLICY COMMITTEE

Co-Chairs: Prof Katie Flanagan, Dr Candice Holland
Members: Prof Margie Danchin, Dr Nila Dharan, Prof Lindsay Grayson, Dr Nigel Raymond, Prof Fiona Russell, Dr Phoebe Williams, Dr Trent Yarwood

ASID EQUITY AND DIVERSITY COMMITTEE

Chair: Dr Rekha Pai Mangalore *(pictured below)*
Members: Dr Nadia Chaves, Dr Emily Woolnough, Assoc Prof Julia Clark, Dr Dani Lin

ASID NEW ZEALAND

Chair: Dr Michelle Balm
Past Chair: Dr Nigel Raymond
Treasurer: Dr Arthur Morris
Webmaster/NZBUG Moderator: Dr Richard Everts
Members: Dr Rachel Webb, Dr Kerry Read, Dr Kate Grimwade, Dr Susan Morpeth, Dr Juliet Elvy, Dr Brendan Arnold, Dr Heather Isenman.
Trainee Representative: Michael-John Fay

ASID INTREPID INTRODUCTORY TRAINEE EDUCATION PROGRAM IN INFECTIOUS DISEASES

Chair & ASID Council Trainee Rep: Dr Annaleise Howard-Jones *(Dr Danielle Fitzpatrick assumed the role in early 2024).*
Members: Dr Priya Garg, Dr Sadid Khan, Dr Steve Muhi, Dr Naomi Whyler, Dr Michelle Mahony, Dr Michelle Sam, Dr Alyssa Pradhan, Dr Imal Hemachandra, Dr Ethan MacMinn, Dr Stuart Campbell, Dr Holly Jordan, Dr Danielle Fitzpatrick, Dr Emma Smith, Dr Victoria Jordan, Dr Phillipa Edmiston

Events & Meetings

ASM 2023

Pink sashes, a glam room, a gala ball, an ASID cocktail, a recipe book, a media wall, *Dance your PhD*, poster submissions with videos, yoga, an interactive quiz and a social media phenomenon from the US. It was an ASM with a difference!

Thank you to all local & international speakers, delegates, & Co-Convenors Drs Celia Cooper and Brett Ritchie along with their enthusiastic organising committee. With a focus on The Immunocompromised Host, Inborn Errors of Immunity and Infections in Resource Limited Settings, more than 380 delegates enjoyed ***The New World of ID*** event held at the iconic Adelaide Oval on 3-5 April 2023.

Lunch time Special Interest Group (SIG) excursions were a highlight:
Art Gallery of South Australia
Detmold factory
Old Adelaide Gaol
Adelaide Zoo
Adelaide Botanical Gardens Herbarium
Australian Space Discovery Centre
BioCina manufacturing facility

Thank you to our Sponsors:
Pfizer - Platinum
Gilead - Silver
GSK - Bronze Astra Zeneca - Bronze MSD - Bronze
Moderna - Trainee Brunch
BiomeBank - Exhibition
Clinpath Pathology - Coffee Cart

Adelaide 2023

Open to the public, close to 1000 adoring fans were in the audience for *An Evening with Dr Glaucomflecken!*
Will Flanary, MD, is an ophthalmologist and comedian who moonlights as US based Dr Glaucomflecken and creates medical-themed comedy shorts for more than three million viewers. Initially used as an outlet to cope with personal health challenges, Dr. Flanary's comedy has universal appeal and has evolved to incorporate biting satire of the US health care system, academic publishing and interpersonal conflicts pervasive universally in the medical system.
PS He was introduced to the joys of AFL while he was here!
His visit was covered by The Age newspaper.

The 2023 Macfarlane Burnet Orator Prof Piero Olliaro, Professor of Poverty Related Infectious Diseases at the University of Oxford, receiving his Life Member award. Prof Olliaro was interviewed for the Sunday Extra program on ABC Australia Radio National while he was in Australia.

Events & Meetings

Thanks to all members and SIGS who took the time to help organise and run meetings and webinars. Some highlights are covered in the next few pages.

Trainee Symposium

Held on 1 April 2023, it featured a full academic program and was held at the Adelaide Zoo. Special ASM guest Dr Glaucomflecken made an appearance.

ICHSIG TID Symposium

The Transplant Infectious Disease (TID), a section of The Transplantation Society (TTS), jointly hosted a TID-focused meeting with ICHSIG. Held on 2 April 2023 at the South Australian Health and Medical Research Institute, Adelaide, more than 90 attendees heard local and international speakers speak *(right).*

ZOOSIG Joint webinar

ZOOSIG collaborated with the Sydney Infectious Diseases Institute (USYD) and the Australian Veterinarians in Public Health SIG (Australian Veterinary Association) to co-host a webinar in March *An International One Health Perspective on Q fever*. There were over 150 registrations including international attendees like the Tanzania-based team in Moshi *(right)*.



Events & Meetings

Mycology Masterclass

Approximately 125 delegates attended the Masterclass in Kingscliff on 2-4 November. It is held every two years and is internationally recognised as a valuable and prestigious advanced training program in medical mycology. This year a special milestone was celebrated!

Joint webinar ANZMIG - ASIA Fungal Working Group - ISHAM

Held on the 25 July 2023 the topic was *CRYPTOCOCCOSIS: Focus on persons without HIV.*

INTREPID

Another full program of fortnightly webinars was delivered for the **IN**troductory **TR**ainee **E**ducation **P**rogram in **I**nfectious **D**iseases. Well done to Dr Annaleise Howard-Jones and the team for creating such an engaging program.

Events & Meetings

NZ Meeting

New Zealand members gathered in Christchurch in September 2023 for their Annual Meeting. Kudos to Sarah Metcalf and everybody involved in organising the meeting.

The Best Trainee Oral Presentation was awarded to Dr Aliya Bryce (above left) for *The Effect of Co-trimoxazole Melioidosis Prophylaxis on Rates of Staphylococcus aureus Bacteraemia in Haemodialysis Patients in the Northern Territory*.

2023 Award Winners

Frank Fenner Award: Assoc Prof Eric Chow
AT Best Poster Award: Dr Brennan Collis
ANZPID: Mr Ben Townley
ANZMIG: Dr Shio Yen Tio
HICSIG: Dr Alice Liu
ICHSIG: Dr Alyssa Pradhan
VACSIG: Dr Archana Koirala
VHSIG: Dr Manoshi Perera
ZOOSIG (Barrie Marmion Award): Dr Michelle Mahoney
John Forbes Travelling Scholarships: Dr Gabriela Ak & Prof Valsan Verghese
National Mentorship Award: Prof David Burgner
Council Scholarship: Dr Rekha Pai Mangalore
AT Travel Award: Dr Annaleise Howard Jones
ASID Research Grant Award: Dr Chris Chew
ANZMIG Research Grant Award: Dr Aiken Dow

*Congratulations to **Assoc Prof Eric Chow** - accepting the **Frank Fenner Award for Advanced Research in Infectious Diseases** from President Prof Katie Flanagan.*

*Congratulations to **Prof Monica Slavin** who was made a **Life Member.***

2023 Award winners

Glam squad!

National Mentorship Award recipient Prof David Burgner

John Forbes Travelling Scholarship recipient Dr Gabriela Ak

VACSIG Award recipient Dr Archana Koirala

Council Scholarship recipient Dr Rekha Pai Mangalore

Advocacy & Campaigns

ASID advocated on many important issues in 2023.

ASID and ANZPID made separate submissions to the Commonwealth Government COVID-19 Response Inquiry. This was an important piece of advocacy given the involvement of all ASID members in the pandemic.

Another key advocacy topic was the proposed Aboriginal and Torres Strait Islander Voice to Parliament. Acknowledging that Aboriginal and Torres Strait Islander peoples experience three times the rate of infectious diseases compared with non-Indigenous people in Australia, ASID advocated for The Voice as an essential step to rebuild trust and ensure equitable access to services and Aboriginal and Torres Strait Islander-led solutions to the health challenges that affect them. While it was not successful, ASID will continue to advocate in this area.

Statements were also put out on vaccination, immunisation, developing the infectious diseases workforce among other topics. At the end of 2023 ASID raised concerns about the expansion of pharmacy prescribing programs for antibiotics for urinary tract infection (UTI), writing to all State and Territory Health Ministers.

At the 2nd Global Forum on Childhood Pneumonia conference in April 2023 ASID and ANZPID pledged to contribute to the prevention and treatment of childhood pneumonia worldwide.

VACSIG put out a statement highlighting World Immunisation Week 2023 to increase awareness around the benefits of immunisation and to encourage Australians and New Zealanders to keep up to date with their vaccinations. It also supported the WSPID Call to Action on Vaccine Inequity.

ASID was a signatory to a letter to the Pharmaceutical Benefits Advisory Committee requesting an amendment to the treatment criteria for hepatitis C in the PBS *'General Statement for Drugs for the Treatment of Hepatitis'*.

Many of ASIDs NZ members met with Te Whatu Ora clinical leaders on the proposal for an Infection Network. The committee is also seeking to maintain some connections with the Ministry, with the focus moving from COVID-19 to more general infection and other public health priorities.

Publications

The ANZPID Journal Club continued with good feedback about the new Quiz Club functionality.

ANZPID wrote a piece for the ASA Journal *ANZPID: A big group passionate about little people* highlighting the work it does in advocating on key issues in child health and infectious diseases.

An updated version of the *Non-occupational post-exposure prophylaxis (nPEP)* guideline was published. It's a stepwise approach for managing children at risk of blood-borne infections and where relevant, sexually transmitted infections, following non-occupational exposure to body-fluids.

The *Healthcare-Associated Infections in Australia: Principles and Practice of Infection Prevention and Control* was endorsed by ASID, with ASID member Professor Ramon Z. Shaban Editor in Chief.

The ASID Immunocompromised Host Special Interest Group was one of seven specialist international societies that have contributed to the development of a core dataset guidelines for the reporting of infection events in immunocompromised patients.

These can all be located on the ASID public website.

Work in Focus

This year, ASID showcased some of the wonderful work our members do. These articles and many more are posted on the ASID public website.

Dr Ameneh Khatami (sixth from left), Clinical Academic in Infectious Diseases and Microbiology at The Children's Hospital at Westmead (CHW) is also Deputy Director of Phage Australia. She wrote about Phage Australia, a national network of phage researchers and clinician scientists bringing phage therapy in as the third major intervention for infectious diseases (after vaccines and antibiotics).

Professor Anna Ralph and the team from the Menzies School of Health Research and Royal Darwin Hospital have developed a smartphone app which condenses the national clinical guidelines on rheumatic fever and rheumatic heart disease.

Dr Aiken Dao from the Sydney Institute of Infectious Diseases was awarded the 2023 ANZMIG Research Grant. Dr Dao is receiving mentorship on his project ***Building the First Australasian Fungal Disease Registry*** from three long-standing senior members of ANZMIG - Assoc Prof Sharon Chen, Prof Orla Morrissey, and Assoc Prof Justin Beardsley.

Dr Phoebe Williams (pictured below) wrote in the Lancet ***New study finds alarming rates of bacterial resistance to drugs used to treat babies and children in the Asia-Pacific region*** which received national and international media coverage.

Secretary's Report

Honorary Secretary
Professor David Paterson
FRACP FRCPA

I would like to welcome all new Full and Associate ASID Members who joined ASID during 2023, and to thank all our ongoing Members for their continued support.

In 2023 ASID started implementing a new membership portal and database system. The new system has a more streamlined renewal process and provides more secure services and better resources for members. As with most tech changes, it has been complex, so I thank all members for their patience and their continued support.

As at 31 Dec 2023 ASID membership grew to **1187** members comprising:

- **Full:** 624
- **Associate:** 496
- **Retired:** 31
- **Honorary:** 36





Please see APPPENDIX for New Associate Members, New Full Members.

Treasurer's Report

Honorary Treasurer
Professor Chris Blyth
FRACP FRCPA

Summary

- Increase in income secondary to delayed subscriptions, a successful ASID ASM and numerous additional meetings in 2023
- Significant increase in the cost of doing business in 2023
- ASID is in a stable financial position

Where to next?

- Investment of significant nest egg in long-term investment strategy with expectation for conservative to moderate returns
- **A full set of accounts will be released by 30 June 2024.**

Full Australian Member: AUD$372 (includes GST for Aust members residing in Aust. Incls a one off $30 joining fee).

Full NZ/Overseas Member: AUD$330 (incls a $30 joining fee)

Associate Australian Member: AUD$159 (includes GST for Aust members residing in Aust. Incls a $30 joining fee).

Associate NZ/Overseas Member: AUD$139 (includes a $30 joining fee).

Retired Australian and NZ/Overseas members pay AUD$36 and AUD$31 per annum respectively.

Life members receive complimentary membership.

Appendix

New members 2023

We welcomed the following new members. Referees are noted next to each members name.

New Associate Members

ACT
Shuba Balan (Stefano Giulieri & Siddhartha Mahanty)
Laura Triggs (Fabian Chiong & Kathryn Daveson)
Nicole Cerruto (Gabrielle O'Kane & Ruchir Chavada)

GERMANY
Julien Coussement (Monica Slavin & Sharon Chen)

NSW
Swati Murugan (Nicole Gilroy & Matthew O'Sullivan)
Karen Chee (Richard Sullivan & Katy Lai)
Bradley Rockliff (Brendan McMullan & Adam Bartlett)
Victoria Deacon (Mrudhula Asogan & Kristen Overton)
Katey Snaith (Aiveen Bannan & Rob Pickles)
Martin Plymoth (Ian Wong & Shobini Sivagnanam)
Mohamed Tashani (Brendan McMullan & Pam Palasanthiran)
David Prabhakar (Ameneh Khatami & Philip Britton)
Sadaf Ahmer (Pam Konecny & Robert Stevens)
Carla Lee Lau (David Paterson & Shradha Subedi)
Isaac Freelander (Archana Sud & Michael Findlay)
Joel Vosu (Ameneh Khatami & Philip Britton)
Samuel Baumgart (Timothy Gray & Elaine Cheong)
Priyali Wijeratne (Brendan McMullan & Adam Bartlett)

NT
Thomas Ewin (Bart Currie & Sonja Janson)
Nilanthy Vigneswaran (Timothy Gray & Elaine Cheong)

NZ
Sarah (Mary De Almeida & Veronica Playle)
Anya Stephensen (Emma Best & Rachel Webb)
Hani Mohd Adnan (Hugh McGann & Paul Huggan)
Shivani Fox-Lewis (Mary De Almeida & Veroncia Playle)
Len Sanders (Chris Mansell & Patrick (Hugh) McGann)
Rebecca Hamblin (Sarah Metcalf & Nicholas Douglas)
Teena Mathew (Annabelle Donaldson & Simon Briggs)

QLD
Kirsten Baulch (Andrew Fuller & Clinton Colaco)
Karen Huynh (Robert Horvarth & Gustinna (Janeth) De Silva)
Rachael Wiedmann (Candice Holland & Kevin Ocallaghan)
Shamila Ginige (Julia Clark & Claire Nourse)
Nadia Hasan (Sophie Wen & Claire Nourse)
Douglas Roche (Kate McCarthy & Sumudu Britton)
Lauren Phillips (Paul Griffin & Jared Eisemann)
Orry Wyer (Kevin O'Callaghan & Karen Lim)
Ryan Perkins (Kimberly Oman & Christopher Heather)
Luke Aaron (Evan Bursle & Kylie Alcorn)
Laura Prideaux (Andrew Mahony & Jason Trubiano)
Mark Fahmy (James Stewart & Simon Smith)

SA
Shamendri Thalpawila (Emily Tucker & Brendan Kennedy)
Jason Teng (David Gordon & Emily Tucker)

TAS
Simran Singh (Emily Tucker & David Gordon)

VIC
Connie Lam (Jason Kwong & Steve Muhi)
Travis Lines (Trisha Peel & Michael Loftus)
Andrés Noé (Nigel Curtis & Josh Osowicki)
Eloise Silvester (Amanda Gwee & Jeremy Carr)
Dhineli Perera (Jason Trubiano & Natasha Holmes)
Vivek Naranbhai (Denis Spelman & Christina Chang)
Hayley Stratton (Jillian Lau & Michael Loftus)
Patricia Griffiths (Jenny Hoy & James McMahon)
Katharine Huang (Cameron Jeremiah & Sam Hume)
Nalian Ibrahim (Claire Dendle & Ian Woolley)
Nelson Wang (Josh Osowicki & Jeremy Carr)
Manogna Metlapalli (Claire Dendle & Ian Woolley)
Chin Eng Goh-Chew (Renjy Nelson & Anushia Ashokan)
Belinda Lambros (Karin Thursky & Abby Douglas)
Elise Mitri (Jason Trubiano & Kyra Chua)
Nicola Sexton-Oates (Andrew Mahony & Adrian Tramontana)
Beau Carr (Sushena Krishnaswamy & Victor Au Yeung)
Danielle Fitzpatrick (Jennifer Hoy & James McMahon)

WA
Stacey Sherwood (Marilyn Hassell & Ohide Otome)
Declan Beauglehole (Claire Italiano & Lynette Pereira)
Daniel Chu (Thel Hla & Arindam Chakravorty)
Maryam Roudbary (Sharon Chen & Justin Beardsley)
Win Myo Thant (Ohide Otome & Andrew Langlands)

Appendix

New Full Members

NT
Kamala Thriemer (Nick Anstey & Josh Davis)

SA
Peter Speck (David Gordon & David Shaw)
Kavita Rasiah (Renjy Nelson & Morgyn Warner)
Chien-Li Holmes-Liew (Nan Vasilunas & Matthew Roberts)

VIC
Eric Chow (Christopher Fairley & Joe Doyle)

WA
Jelena Maticevic (Paul Armstrong & David Speers)

New Retired Members

ACT
Allan Saul (Andrew Steer & Margaret Hellard)

Thank You

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES
ABN 20 108 151 093
ACN 155 632 698
PO BOX Q379 QVB SYDNEY 1230
SUBMISSIONS@ASID.NET.AU

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD
A COMPANY LIMITED BY GUARANTEE

A.B.N. 20 108 151 093

FINANCIAL REPORT

FOR THE PERIOD ENDED 31 DECEMBER 2023

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD
A.B.N. 20 108 151 093

DIRECTORS' REPORT

Your directors present their report on the company for the period ended 31 December 2023.

DIRECTORS

The names of the directors in office at any time during or since the end of the year are:

Prof J Doyle	Prof C Blyth
Prof A Cheng (resigned April 2023)	A/Prof J Clark (resigned April 2023)
Prof K Flanagan	Prof R Stuart (resigned April 2023)
Prof D Paterson	A/Prof C Keighley (appointed April 2023)
Dr R Mangalore (appointed April 2023)	Prof B Marais (appointed April 2023)
Dr N Raymond (appointed Aug 2023)	

The directors have been in office since the start of the financial period to the date of this report unless otherwise stated.

OPERATING RESULTS

The company produced a net profit (loss) for the financial year amounting to 11,992 (2022 loss: $34,084).

REVIEW OF OPERATIONS

A review of the operations of the company during the financial year and the results of those operations are as follows:

- The principal activity of the company during the financial year was to cultivate and promote interest and support in the field of medicine for infectious diseases.
- No significant change in the nature of these activities occurred during the financial year.
- The company was incorporated on 14 September 2018 to take over the operations of the Australasian Society for Infectious Diseases Inc.

MISSION/PURPOSE

The Society is a charitable institution that exists to provide a range of services and support for promoting the treatment and control of infectious diseases and medical conditions, disorders and ailments arising directly from infectious diseases and the consequent impact that infectious disease can have on human health generally, on specific diseases, on public safety, productivity and quality of life generally.

GOALS

Promoting and advancing knowledge and education in all areas of the science and clinical practice of the fields of infectious diseases, clinical microbiology and associated syndromes and ailments;

Convening regular scientific meetings and arranging other research and educational seminars and conferences on infection-related topics in the Australasian region including topics covering the affairs, interest and duties of members of the medical and related health professions and others engaged in the practice, study and control of infectious diseases;

Encouraging and facilitating clinical and laboratory research in the field of infectious diseases;

Awarding research grants from the funds of the Society and establishing scholarships, prizes or awards in such manner as the Board may determine

Engaging with government, agencies and departments to guide and support policy development for the management and control of infectious diseases and antimicrobial resistance;

Facilitating communication between groups and individuals who have an interest in some aspect of infectious disease study, management and control and encouraging professional relationships and understanding of Members.

GOALS (cont'd)

Cooperating with or advising other bodies interested in infectious disease study, treatment, management and control and infectious disease science and communicating with similar organisations in Australia and other parts of the world;

Encouraging public and professional education about the causes and treatment of infectious diseases.

KEY PERFORMANCE MEASURES

The company measures its performance on the basis of sound financial results through prudent management of limited resources and the promotion of research into infectious diseases. The longer term measurement of this success is seen in better patient outcomes for the general public.

EVENTS SUBSEQUENT TO BALANCE DATE

No matters or circumstances have arisen since the end of the financial year which have significantly affected or may significantly affect the operations of the company, the results of those operations, or the state of affairs of the company in future financial years.

LIKELY DEVELOPMENTS

There are no likely developments in the operations of the company, which are expected to affect the results of the company's operations in subsequent financial years.

ENVIRONMENTAL ISSUES

The company's operations are not regulated by any significant environmental regulation under a law of the Commonwealth or of a State or Territory.

DIVIDENDS

The company is limited by guarantee and the Constitution does not permit the distribution of dividends to its members.

No dividends have been paid, declared or proposed by the company since the commencement of the financial year.

DIRECTORS' BENEFITS

Since the commencement of the financial year no director of the company has received or become entitled to receive, a benefit because of a contract that the director, a firm of which the director is a member, or an entity in which the director has a substantial financial interest, has made with:

- The company, or
- An entity that the company controlled or a body corporate that was related to the company, when the contract was made or when the director received, or became entitled to receive, the benefit.

OPTIONS

The company does not have a share capital as it is a company limited by guarantee. Accordingly, no options over interests in the company were granted during or since the end of the financial year and there were no options outstanding at the date of this report.

INSURANCE OF OFFICERS

During the financial year, the Company did not pay a premium to insure certain officers of the company.

PROCEEDINGS ON BEHALF OF THE COMPANY

No person has applied for leave of Court to bring proceedings on behalf of the company or intervene in any proceedings to which the company is party for the purpose of taking responsibility on behalf of the company for all or any part of those proceedings.

The company was not a party to any such proceedings during the year.

DIRECTORS MEETINGS

During the period 31 December 2023, four (4) meetings of the company's directors was held.

For each director, particulars of the relevant numbers of meetings held and attended during the period of directorship are shown below:

Director	Meetings Eligible To Attend	Meetings Attended
	Executive	Executive
Prof C Blyth	4	4
Prof A Cheng	1	1
Prof J Doyle	4	4
Prof K Flanagan	4	4
A/Prof J Clark	1	1
Prof R Stuart	1	0
Prof D Paterson	4	4
A/Prof C Keighley	4	4
Dr R Pai Mangalore	4	4
Prof B Marais	4	4
Dr N Raymond	2	2

DIRECTORS QUALIFICATIONS

Particulars of the directors' experience and special responsibilities (if any) of each director of the company who held office during or since the end of the financial year are:

DIRECTOR	RESPONSIBILITIES / EXPERIENCE
Prof Christopher Blyth	Practising physician in Perth. Professor at School of Medicine University of Western Australia and Director of Wesfarmers Centre for Infectious Diseases FRACP,FRCPA, PhD. In June 2022 elected to the board of the Australasian Society for Infectious Diseases Inc to the position of director.
Prof Allen Cheng	Practicing physician (Alfred Health) MBBS (1993), FRACP (2002) PhD (2005), MPH (2007), MBiostat (2014), GAICD (2017) In May 2018 elected to the Council of the Australasian Society for Infectious Diseases Inc to the position of President from June 2020 to June 2022. On Council since 2013.
Prof Joseph Doyle	Practising consultant in Melbourne, MBBS 2002, MPH 2006, FRACP 2011, FAFPHM 2014, PhD 2015. Elected to Council of ASID in April 2018, Deputy Chair of Viral Hepatitis Special Interest Group in March 2017, and Chair of Finance Committee in August 2018.

DIRECTORS QUALIFICATIONS (cont'd)

Prof Katie Flanagan	Practising consultant (Launceston General Hospital, Tasmania) MBBS (1992) DTM&H (1994) PhD (2000) CCST (2004) FRCP(UK) (2009) FRACP (2013). In 2018 elected to the Council of the Australasian Society for Infectious Diseases Inc to the position of Honorary Secretary until June 2021. Elected President in June 2022. On Council since 2013.
A/Prof Julia Clark	Director of Infectious diseases/Immunology/Rheumatology at Queensland Children's Hospital. On various ASID committees since 2012. Her clinical experience encompasses Infectious Disease/Immunology training and consultant experience in the UK, from developing and delivering national ID training programmes to leading and managing an Infection Management Service in Queensland.
Prof Rhonda Stuart	Medical Director of Infection Prevention and Epidemiology at Monash Health and Director of South-East Local Public Health Unit. She is an ID Physician and a Professor at Monash University. She is a member of the National Prescribing Service Antimicrobial Resistance Reference Group.
Prof David Paterson	Tenured Professor of Medicine at the Saw Swee Hock School of Public Health and the Yong Loo Lin School of medicine, both at the National University of Singapore. M.N., B.S. (Hons), PhD, F.R.A.C.P. F.R.C.P.A. He is also an Honorary Professor at the University of Queensland. He directs ADVANCE-ID (ADVANcing Clinical Evidence for Infectious Diseases). An ID Physician and author of over 490 peer-reviewed publications and is ranked in the top 10 worldwide in the field of microbial drug resistance. He has been a Clarivate Highly Cited Researcher annually from 2015-2020. Appointed to the board in 2021.
A/Prof Caitlin Keighley	Microbiologist and infectious disease physician. MBBS Bmed Sc (Hon) FRCPA, FRACP, DRANZCOG. She works at Southern IML Pathology, and is an adjunct Associate Professor at the University of Wollongong. Active contributor to ANZMIG for ten years and is completing a PhD in mycology. She is also an active member of the Wollongong Antimicrobial Resistance Research Alliance (WARRA). Appointed to the board in 2023.
Dr Rekha Pai Mangalore	Infectious Diseases Physician with experience working across public and private sectors. MBBS, FRACP (General Medicine 2016; Infectious Diseases, 2018) MPH (UNSW), DTM&H (JCU). She is an Infectious Diseases Advanced trainee (RACP) supervisor and mentor; and also supports and mentors medical students, particulary those from overseas from diverse backgrounds. Chair of ASID equity and Diversity. Appoined to the board in 2023.
Prof Ben Marais	Paediatric Infectious Disease Physician at Westmead Children's Hospital. BMedSc, MBChB, MMed (Paed), MRCP (UK), FRACP, PhD. Within the University of Sydney he is the acting Director of the Sydney Infectious Diseases Institute. Appointed to the board in 2023.
Dr Nigel Raymond	Infectious Diseases & General Physician at Capital & Coast (Wellington).Te Whatu Ora. MB ChB, FRACP. An Honorary Clinical Senior Lecturer at the University of Otago and advises on IPC for Evolution Healthcare, Wellington. Past Chair NZ ASID Committee. Involved in progressing infectious diseases priorities with the new government entities following recent New Zealand health reforms. Member of ASID's Policy and Advocacy Committee. He is a member of the NZ Ministry of Health COVID 19 Therapeutic Advisory Group (TAG) and chairs the COVID-19.Therapeutics TAG. He is a member of PHARMAC's COVID-19 Treatments Advisory Group. Appointed to the board in 2023.

The company is registered with the Australian Securities and Investments Commission as well as the Australian Charities and Not-for-profit Commission and is a company limited by guarantee. If the company is wound up, the constitution states that each member is required to contribute a maximum of $1.00 each towards meeting any outstanding obligations of the entity. At 31 December 2023, the total amount that members of the company are liable to contribute if the company is wound up is $1,151.00

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

DIRECTORS' REPORT (CONT'D)

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 7.

Signed in accordance with a resolution of the Board of Directors:

Director:

Dated this day of 2024

AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 60-40C OF AUSTRALIAN CHARITIES AND NOT-FOR PROFIT COMMISSION ACT 2012

In accordance with Subdivision 60-C of the Australian Charities and Not-for-profit Commission Act 2012, I am pleased to provide the following declaration of independence to the directors of Australasian Society for Infectious Diseases Ltd.

I declare that, to the best of my knowledge and belief, during the period ended 31 December 2023 there has been:

(i) no contraventions of the auditor's independence requirements as set out in the Australian Charities and Not-for-profit Commission Act 2012 in relation to the audit; and

(ii) no contraventions of any applicable code of professional conduct in relation to the audit.

MARK TINWORTH
CHARTERED ACCOUNTANT

North Sydney, 2024

INDEPENDENT AUDIT REPORT
TO THE MEMBERS OF AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

Opinion

We have audited the attached financial report of Australasian Society for Infectious Diseases Ltd ("the entity") which comprises the statement of financial position as at 31 December 2023, the statement of profit or loss and other comprehensive income, statement of recognised income and expenditure, cash flow statement for the period then ended, and notes to the financial statements, including a summary of significant accounting policies, other explanatory notes and the Directors' Report.

In our opinion, the accompanying financial report of Australasian Society for Infectious Diseases Ltd is in accordance with Division 60 of the Australian Charities and Not-for-profit Commission Act 2012, including:

1. giving a true and fair view of the Company's financial position as at 31 December 2023 and of its financial performance for the period then ended; and

2. complying with Australian Accounting Standards, and Division 60 of the Australian Charities and Not-for-profit Commission Act 2012 (ACNC Act 2012).

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Directors in accordance with the auditor independence requirements of the ACNC Act 2012 and the ethical requirements of the Accounting Professional and Ethical Standard Board's APES 110: *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.

Responsibilities of the Directors for the financial report

The directors are responsible for the preparation and fair presentation of the financial report that gives a true and fair view and have determined the basis of preparation described in Note 1 to the financial report is appropriate to meet the requirements of the ACNC Act and is appropriate to meet the needs of the members. The directors' responsibility also includes such internal control as the directors determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

- Identify and assess the risks of material misstatements of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis of our opinion. The risk of not detecting material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, international omissions, misrepresentations, or the override of internal control

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Committee's internal control

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

- Conclude on the appropriateness of the company's use of going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion.

- Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieved fair representation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

MARK TINWORTH
CHARTERED ACCOUNTANT

North Sydney 2024

TINWORTH & Co
CHARTERED ACCOUNTANTS and BUSINESS ADVISORS

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

DIRECTORS' DECLARATION

The directors of the company declare that:

1. The financial statements and notes, as set out on pages 11 to 27 are in accordance with the requirements of the Australian Charities and Not-for-profit Commission Act 2012 and:

   (a) comply with Australian Accounting Standards applicable to the entity; and

   (b) give a true and fair view of the company's financial position as at 31 December 2023 and of its performance for the period ended on that date of the company.

2. In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is signed in accordance with subs 60.15(2) of the Australian Charities and Not-for-profit Commission Regulation 2013.

Director:

Dated this day of 2024

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 31 DECEMBER 2023

	Note	2023	2022
		$	$
Revenues	2	1,177,146	691,290
Employee benefits expense		(338,610)	(256,051)
Depreciation expenses		(23,215)	(2,671)
Conference expenses		(554,471)	(357,321)
Special interest group expenses		(21,369)	(19,280)
Administration expenses		(227,489)	(90,051)
Profit (loss) before income tax	3	11,992	(34,084)
Income tax expense	1	-	-
Profit after income tax		11,992	(34,084)
Other comprehensive income after income tax		-	-
Total comprehensive income for the year		-	-
Total comprehensive income attributable to members of the entity		11,992	(34,084)

The accompanying notes form part of these financial statements

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2023

	Note	2023	2022
		$	**$**
CURRENT ASSETS			
Cash and cash equivalents	4	2,046,848	1,912,914
Other assets	5	43,076	100,524
TOTAL CURRENT ASSETS		2,089,924	2,013,438
NON-CURRENT ASSETS			
Property, plant and equipment	6	41,844	61,058
TOTAL NON-CURRENT ASSETS		41,844	61,058
TOTAL ASSETS		2,131,768	2,074,496
CURRENT LIABILITIES			
Trade and other payables	7	83,089	31,862
Short term provisions	8	12,525	18,472
TOTAL CURRENT LIABILITIES		95,614	50,334
TOTAL LIABILITIES		95,614	50,334
NET ASSETS		2,036,154	2,024,162
EQUITY			
Retained Earnings		2,036,154	2,024,162
TOTAL EQUITY		2,036,154	2,024,162

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

STATEMENT OF RECOGNISED INCOME AND EXPENDITURE FOR THE PERIOD ENDED 31 DECEMBER 2023

	Retained Earnings
	$
Balance 1 January 2021	2,058,246
Profit (Loss) for the 2022 year	(34,084)
Balance as at 31 December 2022	2,024,162
Profit (Loss) for the 2023 year	11,992
Balance as at 31 December 2023	2,036,154

The accompanying notes form part of these financial statements.

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

STATEMENT OF CASH FLOWS
FOR THE PERIOD ENDED 31 DECEMBER 2023

	Note	2023	2022
		$	$
CASH FLOWS FROM OPERATING ACTIVITIES			
Members' & Customers' Receipts		1,138,207	669,457
Interest Received		28,256	11,832
Payments to Suppliers & Donations		(1,028,529)	(849,243)
Net Cash Generated from Operating Activities	11	137,934	(167,954)
Cash Flows From Investing Activities			
Purchase of plant		(4,000)	(54,490)
Net Cash Generated from Investing Activities		(4,000)	(54,490)
Net Increase (Decrease) in Cash Held		133,934	(222,444)
Cash at the Beginning of The Financial Year		1,912,914	2,135,358
Cash at the End of the Financial Year	4	2,046,848	1,912,914

The accompanying notes form part of these financial statements.

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

This financial report covers the Australasian Society for Infectious Diseases Ltd as an individual entity. The Australasian Society for Infectious Diseases Ltd is a company limited by guarantee.

The financial statements were authorised for issue on 28 June 2024.

Basis of preparation

The financial report is a general purpose financial report that has been prepared in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) and the Australian Charities and Not-for-profit Commission Act 2012. The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards. Material accounting policies adopted in the preparation of this financial report are presented below and have been consistently applied unless otherwise stated.

The financial statements, except for the cash flow information, have been prepared on an accruals basis and are based on historic costs, modified, where applicable by the measurement at fair value of selected non-current assets, financial assets and financial liabilities. The amounts presented in the financial statements have been rounded to the nearest dollar.

Income Tax

No provision for income tax has been raised as the entity is exempt from income tax under Division 50 of the Income Tax Assessment Act 1997.

Financial Instruments

Initial recognition and measurement

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions to the instrument. For financial assets, this is the date that the Company commits itself to either the purchase or sale of an asset.

Financial instruments (except for trade receivables) are initially measured at fair value plus transaction costs, except where the instrument is classified “at fair value through profit or loss”, in which case the transaction costs are expensed to profit or loss immediately. Where available, quoted prices in an active market are used to determine fair value. In other circumstances, valuation techniques are adopted.

Trade receivables are initially measured at the transaction price if the trade receivable do not contain a significant financing component or if the practical expedient was applied as specified in AASB 15.63.

Classification and subsequent measurement

Financial liabilities

Financial liabilities are subsequently measured at:

- Amortised cost, or
- Fair value through profit and loss

A financial liability is measured at fair value through profit and loss if the financial liability is:
- A contingent consideration of an acquirer in a business combination to which AASB 3 applies
- Held for trading, or
- Initially designated as at fair value through profit and loss

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Financial liabilities (cont'd)

All other financial liabilities are subsequently measured at fair value, amortised cost using the effective interest rate. The effective interest rate method is a method of calculating the amortised cost of a debt instrument and of allocating interest expense in profit or loss over the relevant period.

The effective interest rate is the internal rate of return of the financial asset or liability. That is, it is the rate that exactly discounts the estimated future cash flows through the expected life of the instrument to the net carrying amount at initial recognition.

Financial asset

Financial assets are subsequently measured at:

- Amortised cost
- Fair value through other comprehensive income
- Fair value through profit and loss

Measurement is on the basis of the two primary criteria:

- the contractual cash flow characteristics of the financial asset, and
- the business model for managing the financial assets

A financial asset is subsequently measured at amortised cost when it meets the following conditions:

- the financial asset is managed solely to collect contractual cash flows; and
- the contractual terms within the financial asset give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding on specified dates.

A financial asset is subsequently measured at fair value though other comprehensive income when it meets the following conditions:

- the contractual terms within the financial asset give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding on specified dates: and
- the business model for managing the financial asset comprises both contractual cash flows collection and the selling of the financial asset.

By default, all other financial assets that do not meet the conditions of amortised cost and fair value through other comprehensive income's measurement condition are subsequently measured at fair value through profit and loss.

The entity initially designates financial instruments as measured at fair value through profit and loss if:

- it eliminates or significantly reduces a measurement or recognition inconsistency that would otherwise arise from measuring assets or liabilities or recognizing the gains and losses on them on different bases.
- It is in accordance to the documented risk management or investment strategy and information about the groupings was documented appropriately, so the performance of the financial liability that was part of the entity of financial liabilities or financial assets can be managed and evaluated consistently on a fair value basis; and
- It is a hybrid contract that contains an embedded derivative that significantly modifies the cash flows otherwise required by the contract.

Derecognition

Derecognition refers to the removal of a previously recognised financial assert or financial liability from the statement of financial position.

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Derecognition (cont'd)

Derecognition of financial liabilities:

A liability is derecognised when it is extinguished. An exchange of an existing financial liability for a new one with substantial modified terms, or a substantial modification to the terms of a financial liability, is treated as an extinguishment of the existing liability and recognition of a new financial liability.

The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognised in profit or loss.

Derecognition of financial assets:

A financial asset is derecognised when the holder's contractual rights to its cash flows expires, or the asset is transferred in such a way that all the risks and rewards of ownership are substantially transferred.

All of the following criteria need to be satisfied for derecognition of financial asset:

- The right to receive cash flows from the asset has expired or been transferred;
- All risk and rewards of ownership of the asset have been substantially transferred; and
- The entity no longer controls the asset

On derecognition of a financial asset measured at amortised cost, the difference between the asset's carrying amount and the sum of the consideration received and receivable is recognised in the profit or loss.

Impairment

The company recognises a loss allowance for expected credit losses on financial assets that are measured at amortised cost or fair value through other comprehensive income.

Loss allowance is not recognised for financial assets measured at fair value through profit or loss.

Expected credit losses are the probability-weighted estimate of credit losses over the expected life of a financial instrument. A credit loss is the difference between all contractual cash flows that are due and all cash flows expected to be received, all discounted at the original effective interest rate of the financial instrument.

General approach

Under the general approach, at each reporting period, the company assesses whether the financial instruments are credit-impaired, and:

- If the credit risk of the financial instrument has increased significantly since initial recognition, the Entity measures the loss allowance of the financial instruments at an amount equal to the lifetime expected credit losses; and
- If there has been no significant increase in credit risk since initial recognition, the Entity measures the loss allowance for that financial instrument at an amount equal to 12-month expected credit losses.

Recognition of expected credit losses in financial statements

At each reporting date, the company recognise the movement in the loss allowance as an impairment gain or loss in the statement of profit or loss and other comprehensive income.

The carrying amount of financial assets measured at amortised cost includes the loss allowance relating to that asset.

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Impairment (cont'd)
Assets measured at fair value through other comprehensive income are recognised at fair value with changes in fair value recognised in other comprehensive income. The amount in relation to change in credit risk is transferred from other comprehensive income to profit or loss at every reporting period.

Impairment of Assets

At each reporting date, the Company reviews the carrying values of it tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the assets fair value less cost to sell and value in use, is compared to the asset's carrying value. Any excess of the asset's carrying value over its recoverable amount is recognised in profit or loss.

Where the assets are not held primarily for their liability to generate net cash inflows – that is, they are specialised assets held for continuing use of their service capacity – the recoverable amounts are expected to be materially the same as fair value.

Where it is not possible to estimate the recoverable amount of an individual asset, the entity estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Where an impairment loss on a revalued individual asset is identified, this is recognised against the revaluation surplus in respect of the same class of asset to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that class of asset.

Depreciation of Plant and Equipment
Each class of property plant and equipment is carried at cost or fair value less, where applicable, any accumulated depreciation.

Plant and equipment are measured on the cost basis. All assets are depreciated using the straight line basis so as to write off the cost of each asset over its expected useful life to the company.

Depreciation rates used for each class of asset are:

Class of fixed asset	Depreciation rate
Plant and Equipment	10.0%
Fixtures and Fittings	12.5%

An asset carrying amount is written down immediately to its recoverable amount if the assets carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposal are determined by comparing proceeds with the carrying amount. These gains and losses are included in the statement of comprehensive income. When revalued assets are sold, amounts included in the revaluation reserve relating to that asset are transferred to retained earnings.

Lease payments are allocated between the reduction of the lease liability and the lease interest expense for the period.

Lease payments for leases not classified as finance leases under AASB 16 – Leases, are charged as expenses on a straight-line basis over the lease term.

Revenue
The Company is first required to determine whether amounts received are accounted for as Revenue per AASB 15: *Revenue from Contracts with Customers* or Income per AASB 1058: *Income for Not-for-Profit Entities.*

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Revenue (cont'd)
Funding arrangements which are enforceable and contain sufficiently specific performance obligations are recognised as revenue under AASB 15. Otherwise, such arrangements are accounted for under AASB 1058, where upon initial recognition of an asset, the Association is required to consider whether any other financial statement elements should be recognised, with any difference being recognised immediately in profit or loss as income.

Membership revenue is measured at the fair value of the consideration received and is brought to account on receipts basis.

Interest revenue is recognised proportionally using the effective interest rate method, which for floating rate financial assets is the rate inherent in the instrument.

Grant revenue is recognised in the statement of comprehensive income when the entity obtains control of the grant and it is probable that the economic benefits gained from the grant will flow to the entity and the amount of the grant can be measured reliably. If conditions are attached to the grant which must be satisfied before it is eligible to receive the contribution, the recognition of the grant as revenue will be deferred until those conditions are satisfied.

When grant revenue is received whereby the entity incurs an obligation to deliver economic value directly back to the contributor, this is considered to be a reciprocal transaction and the grant revenue is recognised in the statement of financial position as a liability until the service has been delivered to the contributor, otherwise the grant is recognised as revenue on receipt.

Revenue from the rendering of a service is recognised upon delivery of the service to the customer.

All revenue is stated net of the amount of Goods and Service Tax ("GST").

Goods and Services Tax
Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the ATO.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the statement of financial position. Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities, which are recoverable from or payable to the ATO, are presented as operating cash flows included in receipts from customers or payments to suppliers.

Trade and other payables
Trade and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the company during the reporting period which remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

Employee Entitlements
Provision is made for the liability for employee entitlements arising from services rendered by employees to balance date. Employee entitlements expected to be settled within one year together with entitlements arising from wages and salaries and annual leave which will be settled after one year have been measured at their nominal amount. Other employee entitlements payable later than one year have been measured at the present value of the estimated future cash outflows to be made for those entitlements. Contributions are made to an employee superannuation fund and are charged as expenses when incurred. The company has no legal obligation to provide benefits to employees on retirement.

Cash and Cash equivalents
For the purpose of the statement of cash flows, cash includes cash on hand and at call deposits with banks or financial institutions, net of bank overdrafts.

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Critical Accounting Estimates and Judgments
The directors evaluate estimates and judgments incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the company

Key judgements
Performance obligations under AASB 15

To identify a performance obligation under AASB 15, the promise must be sufficiently specific to be able to determine when the obligation is satisfied. Management exercises judgement to determine whether the promise is sufficiently specific by taking into account any conditions specific in the arrangement, explicit or implicit, regarding the promised goods or services. In making this assessment, management includes the nature/type, cost/value. Quantity and the period of transfer related to the goods or services promised.

Comparative figures
When required by accounting standards, comparative figures have been adjusted to conform to changes in presentation for the current year.

Liability of Members'
The company is limited by guarantee. If the company is wound up, Clause 9 of the Constitution states that in the event of there being a deficiency of net assets on winding up, each member and members within one year of ceasing to be members undertake to contribute a sum not exceeding one dollar per person. As at 31 December 2023 the number of members was 1151 (2022 – 1,196 members).

New and Amended Accounting Policies Adopted by the Company

AASB 2021-2: *Amendments to Australian Accounting Standards- Disclosure of Accounting Policies and Definition of Accounting Estimates.*

The Entity adopted AASB 2021-2 which makes some small amendments to a number of standards including the following: AASB 7, AASB 101, AASB 134 and AASB Practice Statement 2.

The adoption of the amendment did not have a material impact on the financial report.

AASB 2022-7 Editorial Corrections to Australian Accounting Standards and Repeal of Superseded and Redundant Standards.

AASB 2022-7 makes various editorial corrections to a number of standards effective for reporting periods on or after 1 January 2023. The adoption of the amendment did not have a material impact on the financial report.

The Entity has adopted all amendments required for the year ended 30 June 2024. The Adoption of these amendments did not have a material impact on the financial report.

New and Amended Accounting Policies Not Yet Adopted by the Company

AASB 2020-1: *Amendments to Australian Accounting Standards Classification of liabilities as Current or Non-Current.*

The amendment amends AASB 101 to clarify whether a liability should be presented as current or non-current. The Entity plans on adopting the amendment for the reporting period ending 30 June 2024.

The amendments is not expected to have a material impact on the financial report once adopted.

	2023 $	2022 $
2. Revenue		
Operating Activities		
Membership Subscriptions	324,044	119,337
Conference Income	744,955	553,799
Special interest group income	79,445	-
Foreign exchange gain	-	5,922
Sundry	446	400
Interest Received	28,256	11,832
	1,177,146	691,290

3. Profit (Loss) from Ordinary Activities

Profit (Loss) from ordinary activities before income tax has been determined after:

	2023 $	2022 $
(a) Expenses:		
Auditor's remuneration:		
- Audit	4,759	4,473
Depreciation of plant and equipment	23,215	2,671
Employee leave provisions	(5,946)	(7,365)

4. Cash and cash equivalents

	2023 $	2022 $
Cash at Bank – Cheque Account	2,046,848	1,711,959
Cash at Bank – Term Deposits	-	200,955
	2,046,848	1,912,914

The effective interest rate on short term deposits was 1.43% and these deposits have an average maturity of ninety two days.

5. Other Current Assets

	2023 $	2022 $
Current		
Prepaid Expenses	22,393	90,524
Other Debtors	20,683	10,000
	43,076	100,524

6. Property, plant and equipment

	2023 $	2022 $
Plant and equipment - at cost	96,678	92,678
Less: accumulated depreciation	(54,834)	(31,620)
	41,844	61,058

	2023	2022
	$	$

6. Property, plant and equipment (Cont'd)

Movement in carrying amounts

Movement in carrying amounts for each class or plant and equipment between the beginning and end of the current financial year

	2023	2022
Balance at the beginning of the year	61,059	9,239
Additions	4,000	54,491
Depreciation expense	(23,215)	(2,671)
Carrying amount at end of year	41,844	61,059

7. Trade and other payables

	2023	2022
Current		
Trade Creditors & Accruals	83,089	31,862
	83,089	31,862

8. Provisions

	2023	2022
Current		
Annual Leave Entitlements	12,525	18,742
Number of employees at year end	4	4

9. Related party transactions

No Director member receives directly or indirectly any fees, bonuses or other remuneration as a consequence of their appointment to the Board.

10. Financial instruments

Financial risk management

The Company's financial instruments consist mainly of deposits with banks, local money market instruments and short-term investments, accounts receivable and payable.

The Company does not have any derivative financial instruments at 31 December 2023.

Financial Risk Management Policies

The Director's overall risk management strategy seeks to assist the Company in meeting its financial targets, whilst minimising potential adverse effects on financial performance. Risk management policies are approved and reviewed by the Directors' on a regular basis.

The totals for each category of financial instruments, measured in accordance with AASB 9 is detailed in the accounting policies to these financial statements, are as follows:

	2023	2022
	$	$

10. Financial instruments (Cont'd)

	2023 $	2022 $
Financial assets		
Cash & cash equivalents	2,046,848	1,912,914
Trade & other receivables	20,683	10,000
	2,067,531	1,922,914
Financial liabilities		
Trade & other payables	83,089	31,882
Less Deferred revenue	-	-
Less GST payable	-	(8,634)
Financial liabilities	83,089	23,248

i. Treasury risk management

A finance committee consisting of senior Board members meet on a regular basis to analyse currency and interest rate exposure and to evaluate treasury management strategies in the context of the most recent economic conditions and forecasts.

ii. Financial risks

The main risks the Company is exposed to through its financial instruments are interest rate risk, liquidity risk and credit risk.

Interest rate risk

All financial assets and liabilities are non-interest bearing except for the following:
Cash assets at an average interest rate for the year of 1.43%

Foreign currency risk

The Company is not exposed to fluctuations in foreign currencies

Interest rate risk

The Company's exposure to interest rate risk, which is the risk that a financial instrument's value will fluctuate as a result of changes in market interest rates and will affect future cash flows or the fair value of fixed rate financial instruments.

Floating rate instruments

	2023 $	2022 $
Cash & cash equivalents	2,046,848	1,912,914

Liquidity risk

Liquidity risk arises from the possibility that the Company might encounter difficulty in settling its debts or otherwise meeting its obligations related to financial liabilities

The Company manages this risk through the following mechanisms:

- preparing forward-looking cash flow analysis in relation to its operational, investing and financing activities;
- obtaining funding from various sources
- maintaining a reputable credit profile
- managing credit risk related to financial assets
- only investing surplus cash with major financial institutions
- comparing the maturity profile of financial liabilities with the realisation profile of financial assets.

10. Financial instruments (Cont'd)

Financial liability and financial asset maturity analysis

	2023 $	2022 $
	Within one year	
Financial liabilities due for payment:		
Trade & other payables excluding deferred income and GST payable	83,089	23,248
Total expected outflows	83,089	23,248
Financial assets – cash flows realisable:		
Cash & cash equivalents	2,046,848	1,912,914
Trade & other receivables	20,683	10,000
Total anticipated inflows	2,067,531	1,922,914
Net (outflows) inflows on financial instruments	1,984,442	1,899,666

Foreign exchange risk
The Company is exposed to fluctuations in foreign currencies due to the New Zealand denominated account held during the period.

Credit risk
Exposure to credit risk relating to financial assets arises from the potential non-performance by counterparties of contractual obligations that could lead to a financial loss to the Company. Credit risk is managed through maintaining procedures ensuring, to the extent possible, that customers and counterparties to transactions are of sound credit worthiness and includes utilisation of systems for that approval, granting and renewal of credit limits, the regular monitoring of exposures against such limits and the monitoring of the financial stability of significant customers and counterparties. Such monitoring is used in assessing receivables for impairment. Credit terms are normally 14-30 days from the date of invoice.

Customers that do not meet the Company's strict credit policies may only purchase in cash or using recognised credit cards.

Risk is also minimised through investing surplus funds in financial institutions that maintain high credit ratings or in entities that the finance committee has otherwise cleared as being financially sound.

The maximum exposure to credit risk by class of recognised financial assets at balance date, excluding the value of any collateral or other security held, is equivalent to the carrying value and classification of those financial assets (net of any provisions) as presented in the balance sheet.

The company has no significant concentration of credit risk with any single counterparty or group of counterparties.

Trade & other receivables that are neither past due or impaired are considered to be of high credit quality aggregates of such amounts are as detailed in Note 5

The Company does not have any material credit risk exposure to any single receivable or group of receivables under financial instruments entered in to by the Company.

Credit risk related to balances with banks and other financial institutions is managed by the finance committee in accordance with approved Committee policy. The following table provides information regarding the credit risk relating to cash based on S&P counterparty credit ratings.

	2023	2022
	$	$
10. Financial instruments (Cont'd)		
Cash and cash equivalents		
- AA- rated	2,046,848	1,912,914

Price risk
The company is not exposed to any material commodity price risk.

Net fair values

Fair value estimation
The fair values of financial assets and financial liabilities are presented in the following table and can be compared to their carrying values as presented in the balance sheet. Fair values are those amounts at which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arms-length transaction. Fair values derived may be based on information that is estimated or subject to judgement, where changes in assumptions may have a material impact on the amounts estimated, Areas of judgement and the assumptions have been detailed below.

Differences between fair values and carrying values of financial instruments with fixed interest rates are due to the change in discount rates being applied by the market since their initial recognition by the company.

	2023		2022	
	Net carrying value	**Net fair value**	**Net carrying value**	**Net fair value**
Financial assets				
Cash & cash equivalents	2,046,848	2,046,848	1,912,914	1,912,914
Trade & other receivables	20,683	20,683	10,000	10,000
Total financial assets	2,067,531	2,067,531	1,922,914	1,922,914
Financial Liabilities				
Trade & other payables	83,089	83,089	23,248	23,248
Total financial liabilities	83,089	83,089	23,248	23,248

The fair values of these financial assets have been based on the closing quoted bid prices at the end of the reporting period, excluding transaction costs.

The fair values disclosed in the above table have been determined based on the following methodologies:

(i) Cash and cash equivalents, trade and other receivables and trade and other payables are short term instruments in nature whose carrying value is equivalent to fair value.

Sensitivity analysis
The following table illustrates sensitivities to the company's exposures to changes in interest rates and equity prices. The table indicates the impact on how profit and equity values reporting at the end of the reporting period would have been affected by changes in the relevant risk variable that management considers to be reasonably possible. These sensitivities assume that the movement in a particular variable is independent of other variables.

	2023	2022
	$	$

10. Financial instruments (Cont'd)

	Profit	Equity
Year ended 31 December 2023	**$**	**$**
+/- 2% in interest rates	39,654	39,654

No sensitivity analysis has been performed on foreign exchange risk as it is not considered to be material to the company.

11. Cash Flow Information

(a) Reconciliation of net cash provided by operating activities to profit (loss) from ordinary activities after income tax

	2023 $	2022 $
Operating Profit (Loss) after Income Tax	11,992	(34,084)
Non-Cash Flows in Operating Profit:		
- Depreciation	23,215	2,671
Changes in Assets and Liabilities:		
- (Increase) Decrease in Other Assets	57,448	(79,852)
- Increase (Decrease) in Payables	51,226	(49,327)
- Increase (Decrease) in Provisions	(5,947)	(7,362)
Net Cash (used in) provided by Operating Activities	137,934	(167,954)

(b) The company has no credit stand-by or financing facilities in place.
(c) There were no non-cash financing or investing activities during the year.

12. Contingent Liabilities and Contingent Assets

The company is not aware of any contingent liabilities that are in existence at the date of the signing of this report.

13. Events after the Balance Sheet Date

There have been no events that occurred after balance date that will have a material effect on the Society or the Society's financial report for the year ended 31 December 2023.

14. Key Management Personnel

	2023 $	2022 $
Short-term employee benefits	130,164	109,914
Post employment benefits	12,840	13,314
	143,004	123,228

15. Company Details

The principal place of business of the company is:
Australasian Society for Infectious Diseases Ltd
145 Macquarie Street
SYDNEY NSW 2000

The company's registered office is:
Australasian Society for Infectious Diseases Ltd
145 Macquarie Street
SYDNEY NSW 2000

TINWORTH & Co
CHARTERED ACCOUNTANTS and BUSINESS ADVISORS

COMPILATION REPORT

TO AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

On the basis of information provided by the directors of the Australasian Society for Infectious Diseases Ltd, we have compiled in accordance with APES 315: 'Statement on Compilation of Financial Reports', the special purpose financial report of the Australasian Society for Infectious Diseases Ltd for the period ended 31st December 2023, as set out in the attached Detailed Profit and Loss Statement.

The specific purpose for which the special purpose financial report has been prepared is to provide private information to the directors. The extent to which Accounting Standards and other mandatory professional reporting requirements have or have not been adopted in the preparation of the special purpose financial report set out in Note 1.

The directors are solely responsible for the information contained in the special purpose financial report and have determined that the accounting policies used are and are appropriate to satisfy the requirements of the directors.

Our procedures use accounting expertise to collect, classify and summarise the financial information, which the directors provided, into a financial report. Our procedures do not include verification or validation procedures. No audit or review has been performed and accordingly no assurance is expressed.

To the extent permitted by law, we do not accept liability for any loss or damage which any person, other than the company, may suffer arising from any negligence on our part. No person should rely on the special purpose financial report without having an audit or review conducted.

The special purpose financial report was prepared for the benefit of the company and its members and the purpose identified above. We do not accept responsibility to any other person for the contents of the special purpose financial report.

MARK TINWORTH
CHARTERED ACCOUNTANT

North Sydney, 2024

WWW.TINWORTH.COM

LEVEL 2, 66 BERRY ST NORTH SYDNEY NSW 2060 | P (02) 9922 4644 | F (02) 9959 3642 | ABN 43 624 513 140

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD
A.B.N. 20 108 151 093

PRIVATE INFORMATION FOR THE DIRECTORS
ON THE 2023 FINANCIAL STATEMENTS

CONSOLIDATED PROFIT AND LOSS STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2023

	2023	2022
INCOME	**$**	**$**
Membership income	324,044	119,337
Conference income	744,955	553,799
Special interest groups	79,445	-
Interest received	28,256	11,832
Sundry income	446	6,322
	1,177,146	691,290
EXPENDITURE		
Audit fees	4,759	4,473
Accountancy fees	4,589	4,893
Bank fees	19,303	9,961
Board expenses	5,174	625
Computer website expenses	43,465	18,025
Conference expenses	554,471	357,321
ANZMIG expenses	10,574	10,985
ANZPID expenses	8,522	6,931
Depreciation	23,215	2,671
VACSIG	1,364	-
VHSIG	909	1,364
Insurance	6,764	7,504
Legal expenses	5,004	-
Rent	2,560	6,807
Meeting expenses	79,764	4,332
Awards & grants	38,128	18,654
Secretariat expenses	17,979	14,777
Secretariat payroll expenses	338,610	256,051
	1,165,154	725,374
Profit before Income Tax	11,992	(34,084)

This financial statement should be read in conjunction with the attached Compilation Report